TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07249905: A Phase 1/2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies

Sponsor: ModeX Therapeutics, An OPKO Health Company · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07249905 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07249905 Rescue Dossier →